Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver
Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver
This is a multicenter, randomized, open-label study to investigate the superiority of the
 contrast enhancement effect of E7337 on tumor-like lesions in the Dynamic CT of the liver.
Inclusion Criteria:

 1. Patients with a tumorous lesion in the liver observed in diagnostic imaging such as
 ultrasonography, etc., conducted between 1 and 35 days before administration of the
 investigational agent, who are scheduled to undergo a dynamic CT examination.

 2. Patients between 20 and 80 years old at the time informed consent is obtained.

 3. Patients weighing >= 55.6 and < 105.0 kg at the time consent is obtained and when the
 investigational agent is administered.

 Exclusion Criteria:Issues affecting the safety evaluation of the investigational agent:

 1. Patients who will have undergone or are scheduled to undergo an examination using
 another contrast agent from 7 days before administration of the investigational agent
 up to the time follow-up examinations are performed on day 8 after administration.

 2. Patients for whom there is a strong possibility that a follow-up period, which extends
 up until examinations are performed on day 8 after administration, would not be
 possible, (i.e., when it will not be possible to evaluate delayed adverse drug
 reactions).

 3. Patients who have undergone or are scheduled to undergo surgical treatment or a
 therapy such as percutaneous ethanol injection therapy, percutaneous microwave
 coagulation therapy, radiofrequency ablation, or transcatheter arterial embolization,
 etc., from the time diagnostic imaging such as abdominal ultrasonography is performed
 up until follow-up examinations are conducted on day 8 after administration.

 4. Patients who are unable to discontinue taking analgesics during the period from the
 morning when the investigational agent is administered until CT examinations are
 completed.

 5. Patients who cannot stop taking biguanide antidiabetic drugs, such as metformin
 hydrochloride and buformin hydrochloride, for three days after study agent
 administration (including administration day).

 6. Patients who are currently participating in another clinical study.

 7. Patients who participated in another clinical study within the 6 months prior to
 providing informed consent to participate in this study.

 General concerns relating to the safety of the subject:

 1. Patients in the acute stage of illness with unstable symptoms, or patients in a
 life-threatening condition (when it is expected that emergency treatment may be
 required between the time of registration and the conclusion of the follow-up period,
 or when the patient is not expected to survive for 3 months following administration
 of the investigational agent, etc.)

 2. Patients with a history of hypersensitivity to iodine or iodinated contrast agents.

 3. Patients with serious thyroid disease (goiter, hyperthyroidism, etc.)

 4. Patients with serious cardiopathy (New York Heart Association [NYHA] functional class
 IV heart failure, shock, cyanosis, peripheral circulatory insufficiency, ventricular
 tachycardia, ventricular fibrillation, or complete atrioventricular block)

 5. Patients with serious hepatopathy [symptoms of liver failure (fulminant hepatitis)
 such as a disturbance of consciousness corresponding to grade 3 in the Criteria for
 Grading Adverse Drug Reactions of Medicinal Products.]

 6. Patients with moderate serious nephropathy (acute kidney failure, chronic kidney
 failure, hydronephrosis, nephrotic syndrome, or uremia with serum creatinine levels of
 2.0 mg/dL or more, corresponding to grade 2 or above in the Criteria for Grading
 Adverse Drug Reactions of Medicinal Products.)

 7. Patients with bronchial asthma

 8. Patients with acute pancreatitis

 9. Patients with macroglobulinemia

 10. Patients with multiple myeloma

 11. Patients with tetany

 12. Patients with pheochromocytoma or who are suspected of having pheochromocytoma

 13. Pregnant and potentially pregnant women, and nursing mothers

 14. Patients with a history of medicine hypersensitivity

 15. Patients with serious myasthenia gravis

 16. Patients judged by an investigator for any other reason to be ineligible for
 participation as a subject in this study.